• One-Stop CAR-T Therapy Development
  • Biomarker Identification & Selection
  • scFv Generation
  • CAR Design & Construction
  • CAR-T Gene Packaging & Delivery
  • Replication-Competent Virus Testing Service
  • CAR Cell In Vitro Assay Service
  • CAR-T Preclinical In Vivo Assay
  • IND Development for CAR-T Cell Therapy
  • GMP Production for CAR-T Products
  • CAR Clinical Trials
• One-Stop TCR-T Therapy Development
  • TCR Biomarker Identification & Selection
  • TCR Generation & Optimization
  • TCR Design & Construction
  • TCR Gene Packaging & Delivery
  • TCR In Vitro Assay
  • TCR-T Preclinical In Vivo Assay
  • TCR Analysis
  • TCR Clinical Applications
• One-Stop CAR-MA Therapy Development
• One-Stop CAR-NK Therapy Development
  • One-stop CAR-NKT Therapy Development
  • One-stop UniCAR-NK Therapy Development
  • iPSC-derived CAR-NK Therapy Development
  • One-stop TCR-NK Therapy Development
  • NK Cell Genetic Engineering Service
  • NK Cell Expansion Service
• One-stop Cytokine Release Syndrome (CRS) Management Solutions
• One-Stop CAR-B Therapy Development
• TCR-Like Antibody Development Service
  • MHC/Peptide Complex Production for TCR-Like Antibody Discovery
  • TCR-Like Antibody Discovery Strategies
  • TCR-Like Antibody Affinity Characterization
  • TCR-Like CAR Construction and Evaluation Service
• γδ T Cells Engineering Services
• One-Stop Canine CAR-T Therapy Development Services
  • Canine CAR-T Engineering Service
  • Canine CAR-T Development Service for Hematologic Malignancies
  • Canine CAR-T Development Service for Solid Tumor
  • Canine CAR-T Cell Characterization Service
• CellRapeutics™ In Vivo Cell Engineering Development Services
  • In Vivo CAR-T Cell Engineering
  • In Vivo B Cell Engineering
  • In Vivo CAR-NK Cell Engineering
  • In Vivo CAR-M Cell Engineering
• scFv-TCR T Cell Therapy Development Service
• One-Stop Silence™ CAR-T Cell Therapy Development Services
• One-Stop mRNA CAR-T Therapy Development
• Vaccine Boosting CAR-T Cell Therapy Solutions Against Solid Tumors
  • Peptide-DC Vaccine Boosting pMHC-directed CAR-T Cell Solutions
  • Amphiphile-ligand Vaccine Boosting CAR-T Cell Solutions
  • RNA Vaccine Boosting CAR-T Cell Solutions
  • Virus-based Vaccine Boosting CAR-T Cell Solutions
• CellRapeutics™ STAb-T Cell Therapy Development
• CellRapeutics™ CART Therapy Development Services in the Non-Cancer Field
  • CellRapeutics™ CART Development Service for Autoimmune Diseases
  • CellRapeutics™ CART Development Service Powering Anti-Aging Field
  • CellRapeutics™ CART Development Service for Fibrotic Diseases
  • CellRapeutics™ CART Development Service Targeting Infectious Diseases
• One-Stop Allogeneic Cell Therapy Development Services
  • Allogeneic CAR-T Therapy Development Services
  • Allogeneic TCR-T Therapy Development Services
  • Allogeneic CAR-NK Therapy Development Services
  • Allogeneic CAR/TCR Cell Design and Engineering Services
  • Other Allogeneic Cell Therapy Development Services
• CellRapeutics™ Anti-HIV CAR Cell Therapy Development
  • HIV CAR Design and Construction
  • HIV CAR Cell Design and Engineering
• CellRapeutics™ Antibody-TCR (AbTCR) Technology
• Organoid-induced Differentiation of Conventional T Cells from hPSCs
• Modular CAR-T Cell Generation with AAV-Cpf1
• High-throughput Screening for T Cell Activity Modulator Discovery
• Nanoparticle Tiny Tech for Programming T Cells
• TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology
  • NR4A Knock Out CAR-T Cell Development with CRISPR Technology
• Virus Specific T Cell (VST) Technology
• Antibody-Coupled T Cell Receptor (ACTR) Platform
• CellRapeutics™ TCR/CAR/Antigen-Engineered Regulatory T Cells (Tregs)
  • CellRapeutics™ CAR-Treg Development
• CellRapeutics™ Chimeric Engulfment Receptor (CER) Technology
• Dendritic Vaccine Development
  • Induction of Antitumor Cytotoxic Lymphocytes Using Engineered Human Primary Blood Dendritic Cells
• Bispecific TCR Development
• Cancer Vaccine Development
  • Cancer Vaccine Discovery
  • Cancer Vaccine Engineering
  • Cancer Vaccine Analytical Characterization
  • Cancer Vaccine In Vivo Assessment
  • Cancer Vaccine GMP Manufacturing
• One-Stop CAR-Monocyte Therapy Development
• Other Services
  • HLA Typing Service
  • KIR Typing Service
  • HLA Testing
  • Tumor-infiltrating Lymphocytes-based Antibody Discovery Service
  • Dog DLA Genotyping Service
  • Guinea Pig GPLA Genotyping Service
  • Mouse H2 Genotyping Service
  • Rabbit RLA Genotyping Service
  • Rat RT1 Genotyping Service
  • Rhesus Macaque MHC Genotyping Service

Allogeneic Evading NK Cell Development Service

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Natural Killer (NK) cells, as crucial elements of the innate immune system, hold substantial promise in cancer immunotherapy and other therapeutic areas. Given their ability to target virally infected and malignant cells without prior sensitization, NK cells represent a powerful tool for adoptive cell transfer therapies. However, autologous NK cell therapies have faced limitations such as functional defects in patients' NK cells. Consequently, attention has shifted towards allogeneic NK cell therapies, particularly with advancements in evading host immune responses. Creative Biolabs provides state-of-the-art services that focus on developing allogeneic evading NK cells to enhance the efficacy and persistence of these cells in therapeutic settings.

Allogeneic Evading NK Cell Development Service at Creative Biolabs

At Creative Biolabs, we employ advanced techniques to develop allogeneic NK cells capable of evading the host immune system, thereby improving their therapeutic potential. Our allogeneic evading NK cell development service leverages proprietary technologies to create NK cells from diverse sources, including induced pluripotent stem cells (iPSCs), and incorporates specific genetic modifications using cutting-edge gene editing techniques to enhance persistence and functionality.

Our Featured Allogeneic Evading Technology

Creative Biolabs prides itself on its proprietary allogeneic evading technology, aimed at enhancing the persistence and effectiveness of allogeneic NK cells by preventing their recognition and elimination by the host's immune system. This technology entails:

• Knockout of beta-2-microglobulin (β2m) and Class II MHC Transactivator (CIITA): This modification prevents CD8+ and CD4+ T cell recognition.
• Knock-in of the HLA-E gene: This enhances the expression of the HLA-E protein, which prevents killing by host NK cells through interaction with NKG2A receptors.
• Use of checkpoint molecules and immune modulators: Strategically incorporates immune checkpoint molecules to avoid NK cell depletion or exhaustion.

Service Workflow

Our service encompasses several key steps designed to create optimized NK cell candidates:

Frequently Asked Questions

Q1: Can Creative Biolabs' allogeneic NK cells be used synergistically with other therapies?

A1: Yes, Creative Biolabs' NK cells can be combined with other therapeutic modalities, including monoclonal antibodies (mAbs), immune checkpoint inhibitors, and other immunomodulatory drugs. This combinatorial approach has the potential to enhance the overall therapeutic efficacy, as evidenced by ongoing clinical trials employing NK cells in combination with other treatments.

Q2: What are the future directions for allogeneic NK cell therapy?

A2: Future directions include the continued development of genetic modifications to enhance NK cell functionality and persistence, identification and targeting of novel CAR targets for CAR-NK therapies, and optimization of therapeutic regimens to enhance the efficacy of allogeneic NK cells. Creative Biolabs is also exploring scalable manufacturing processes to provide "off-the-shelf" NK cell products for broader research applications.

Creative Biolabs remains dedicated to pushing the boundaries of NK cell therapies, with an ongoing commitment to scientific innovation and clinical translation, ensuring that allogeneic NK cells serve as a powerful and versatile tool in the fight against cancer and other diseases.